Cancer in Translation

Filter By:

Article Type
Year
  • Despite substantial advances in understanding of the molecular features of gliomas, the therapeutic options for these aggressive tumors remain scarce. Rich, Mitchell and colleagues provide their views about a phase 1 clinical trial testing the safety and efficacy of vaccines against cancer expressing mutant metabolic enzyme IDH1 in patients with high-grade glioma.

    • Sameer Agnihotri
    • Kailin Yang
    • Jeremy N. Rich
    Cancer in Translation
  • Although RET alterations are relatively frequent across tumor types, specific targeting of RET in the clinic has been challenging. Ambrogio, Aggarwal and colleagues provide their views on how mechanistic studies have swiftly translated into powerful targeted therapies in two recent clinical studies that led to the FDA approval of selpercatinib for certain tumors in which RET is altered.

    • Melina E. Marmarelis
    • Roberto Chiarle
    • Charu Aggarwal
    Cancer in Translation
  • Although cancer genomics is a powerful tool to understand cancer and develop diagnostic tools, the contribution of the microbiome in cancer diagnosis and clinical assessment is much less studied. Elinav, Greten and colleagues provide their respective views on how studying cancer metagenomes could facilitate identification, diagnosis and staging of different tumor types.

    • Lorenz Adlung
    • Eran Elinav
    • Firouzeh Korangy
    Cancer in Translation
  • A new suite of studies from the Pan Cancer Analysis of Whole Genomes (PCAWG) Consortium provides the most detailed resolution of cancer genomes to date, extending our knowledge of driver genes, mutational features, structural alterations and more. Kreisberg, Ideker, Mills and Meric-Bernstam discuss the foundational and translational insights gained from this project.

    • Jason F. Kreisberg
    • Trey Ideker
    • Gordon Mills
    Cancer in Translation
  • KRAS mutations are among the most prevalent tumor drivers, but targeting them pharmacologically has been challenging. Recent landmark studies have demonstrated promising clinical results of KRASG12C inhibition by using small molecules. Bar-Sagi, and Knelson and Sequist provide their distinct perspectives on this recent tour de force in targeting KRASG12C alterations.

    • Dafna Bar-Sagi
    • Erik H. Knelson
    • Lecia V. Sequist
    Cancer in Translation